Company Overview
About Areteia Therapeutics
Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral treatments for eosinophil-driven diseases, particularly severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). The company was formerly known as TPI Therapeutics and rebranded as Areteia upon securing significant venture financing. Its lead compound, dexpramipexole, is a small molecule that selectively inhibits eosinophil maturation in the bone marrow — reducing circulating eosinophil levels by 75-90% without the immunosuppressive effects that can accompany broad anti-inflammatory drugs.
Business Model & Competitive Advantage
Areteia raised $215 million in a Series B financing round in 2023, led by OrbiMed Advisors, with participation from Atlas Venture, EQT Life Sciences, and other healthcare-focused investors. The company is conducting the Phase 3 EXHALE trial of dexpramipexole in patients with uncontrolled severe eosinophilic asthma, targeting patients who do not adequately respond to existing inhaled corticosteroids. Approximately 300,000-500,000 patients in the United States are estimated to have severe eosinophilic asthma.
Competitive Landscape 2025–2026
Dexpramipexole's potential market position is significant: if approved, it would be the first oral eosinophil-depleting therapy — an alternative to injectable biologic therapies such as mepolizumab (Nucala), benralizumab (Fasenra), and dupilumab (Dupixent). The oral route of administration is a meaningful clinical and commercial differentiator, as many patients prefer oral medications over self-injection or infusion. Areteia is also exploring dexpramipexole in other eosinophilic conditions beyond asthma.
Key Differentiators
Emerging Innovator
Areteia Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Compare Areteia Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Areteia Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Areteia Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Areteia Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →